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Cultured tubule cells from TGF-b1 null mice exhibit impaired
hypertrophy and fibronectin expression in high glucose.
Background. To firmly establish the role of the transforming
growth factor-b1 (TGF-b1) isoform in the pathophysiology of
diabetic tubulointerstitial hypertrophy and fibrosis, we exam-
ined how the total absence of TGF-b1 would alter the effect of
high glucose on cellular hypertrophy and matrix expression in
tubuloepithelial cells cultured from TGF-b1 null mice.
Methods. Primary tubule cell cultures, obtained from kidneys
of TGF-b1 knockout mice and their wild-type littermates, were
treated with exogenous TGF-b1 or high glucose. The TGF-b
system was characterized at the ligand and receptor levels us-
ing Northern and Western blotting. Cellular hypertrophy and
growth were assessed by thymidine incorporation, cell count-
ing, leucine incorporation, and protein content. Fibronectin ex-
pression was assessed by Northern analysis and enzyme-linked
immunosorbent assay (ELISA).
Results. Knockout cells did not express TGF-b1 but did ex-
press TGF-b2, TGF-b3, and TGF-b type I and type II receptors.
Exogenous TGF-b1 down-regulated the ligand-binding type II
receptor but up-regulated type I receptor expression. Knockout
cells proliferated more rapidly than wild-type cells, but restoring
TGF-b1 to knockout cells slowed their proliferation. In wild-
type cells, high glucose caused cellular hypertrophy, evidenced
by greater leucine incorporation and protein content along with
decreased thymidine incorporation. High glucose also increased
fibronectin message and protein. However, in knockout cells,
high glucose failed to induce hypertrophy and was severely lim-
ited in its capacity to stimulate fibronectin.
Conclusion. In tubular epithelial cells, TGF-b1 mediates
the hypertrophic and fibronectin-stimulatory effects of high
glucose, confirming the role of the TGF-b1 isoform in the patho-
genesis of diabetic tubular hypertrophy and fibronectin overex-
pression.
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Several manifestations of diabetic nephropathy are
consequences of altered protein production in response
to cytokines or growth factors [1]. Our group has fo-
cused on transforming growth factor-b (TGF-b) because
it plays a central role in mediating the effects of high
ambient glucose on renal cells [2]. High glucose pro-
motes cellular hypertrophy and stimulates extracellular
matrix production [3, 4] in cultured mesangial cells [5,
6], glomerular epithelial cells [7, 8], and proximal tubular
cells [9, 10]. In turn, these high glucose effects are inhib-
ited by blocking the autocrine activation of the TGF-b
system, suggesting that high glucose acts through a TGF-
b–dependent mechanism [6, 11]. Similarly, the deleteri-
ous effects of diabetes on the kidney may be mediated by
TGF-b overactivity, and the increased renal expression
of TGF-b1 and its type II signaling receptor serve to ag-
gravate the renal injury in diabetes [12–14]. Further proof
of TGF-b stimulation in the diabetic kidney can be found
in the activation of the Smad pathway that transmits the
TGF-b signal [15, 16].
If TGF-b overactivity is causal, then inhibition of
TGF-b should successfully treat diabetic nephropathy. In
the streptozotocin-diabetic mouse, panselective neutral-
izing anti-TGF-b antibodies decreased renal hypertrophy
and prevented the overexpression of glomerular matrix
proteins in the short-term (9 days) [17]. In a long-term
study (8 weeks) of the type 2 diabetic db/db mouse, pans-
elective anti-TGF-b antibodies also attenuated matrix
overexpression, prevented mesangial glomerulosclerosis,
and averted the development of renal insufficiency [18].
Lastly, anti-TGF-b antibodies can even reverse the estab-
lished lesions of diabetic glomerulopathy [19]. Although
anti-TGF-b therapy was started well after the onset of
diabetes in the db/db mouse [19], glomerular basement
membrane thickening and mesangial matrix expansion
were both significantly improved with treatment, impli-
cating TGF-b as the predominant cytokine effector of
diabetic kidney disease.
1191
1192 Chen et al: High glucose on TGF-b1 knockout cells
In the above studies, the use of panselective anti-TGF-
b antibodies that neutralize all three mammalian iso-
forms of TGF-b (TGF-b1, -b2, and -b3) does not allow
for the elucidation of the relative roles of each of the three
isoforms in the pathogenesis of diabetic nephropathy. Al-
though there are indirect hints that the TGF-b1 isoform
is the principal mediator of diabetic renal lesions [20, 21],
direct proof is largely lacking. It would be desirable to
use the TGF-b1 knockout mouse to confirm the selective
role of the TGF-b1 isoform in diabetic kidney disease,
but unfortunately these animals die at an early age from
a diffuse inflammatory disorder, making the chronic study
of diabetes in these animals impossible [22–25]. Instead,
we established primary cultures of tubular epithelial cells
from the kidneys of young TGF-b1 knockout mice (−/−)
and their wild-type littermates (+/+) [26, 27].
Tubular cells were isolated because, in some respects,
the tubulointerstitium plays the more significant role
in the progression of diabetic renal disease. In fact,
the extent of tubulointerstitial fibrosis correlates most
closely with the prognosis for end-stage renal disease
from any cause, including diabetes [28, 29], and tubular
hypertrophy, with the attendant increase in reabsorp-
tion and decrease in glomerular filtrate reaching the
macula densa, may activate tubuloglomerular feedback
and beget glomerular hyperfiltration, which is detrimen-
tal in its own right [30]. This emphasis on the primary
role of tubulointerstitial abnormalities in the genesis
of glomerular functional defects has been aptly termed
the “tubulocentric” view of diabetic nephropathy [30].
Thus, it remains important to investigate the mechanisms
whereby tubular hypertrophy and fibrosis are caused by
the metabolic features of diabetes. With this in mind, we
examined how the pathobiologic effects of high ambient
glucose are altered by the total absence of TGF-b1 in re-
nal tubular cells with respect to cellular hypertrophy and
matrix expression.
METHODS
Establishment of cell lines
Tubular epithelial cells were isolated from the kidneys
of TGF-b1 knockout mice and their control littermates
(strain background C57BL/6) by a modification of the
method described by Taub and Sato [31]. The TGF-b1
knockout mouse breeding colony and the normal litter-
mates were maintained at the National Institute of Di-
abetes and Digestive and Kidney Diseases (NIDDK).
Briefly, mice were killed at 1 week of age. Kidney cor-
tices were dissected from the medulla, sliced, and minced
on a metal mesh. Glomeruli were removed by differential
sieving, and the remaining tissue was digested in collage-
nase to isolate tubular cells. Primary cultures were grown
in renal epithelial growth medium containing 130 mg/dL
D-glucose, 0.5% fetal calf serum (FCS), human epi-
dermal growth factor, insulin, hydrocortisone, gentam-
icin, amphotericin B, epinephrine, triiodothyronine, and
transferrin (REGM Bullet Kit) (Cambrex BioScience,
Walkersville, MD, USA). To exclude the outgrowth of
fibroblasts, primary cell cultures were maintained for at
least 10 days in serum-deprived media. Clonal cell lines
were propagated from the kidneys of two TGF-b1 knock-
out mice, knockout 2.3 and knockout 2.4, and two wild-
type littermates, wild-type 1.2 and wild-type 3.5. All of
the cell lines express the epithelial cell markers, cytoker-
atin and uvomorulin (E-cadherin), and are negative for
smooth muscle actin, desmin, and vimentin, consistent
with a tubular epithelial phenotype [26, 27]. Further, the
wild-type and knockout cells display lotus lectin binding,
which is more characteristic of a proximal tubular cell
[26].
Cell culture experiments
Cells were maintained at 37◦C in a humidified incu-
bator with 5% CO2 and propagated in REGM/0.5%
FCS containing 130 mg/dL D-glucose (“normal glucose”).
The cells were passaged every 5 to 7 days by light
trypsinization. Wild-type and knockout cells were care-
fully matched for passage number (between 3 and 17)
and were plated at identical densities for the experi-
ments outlined in this study. Experiments were initiated
by resting the cells for 24 hours in REGM/0% FCS, and
then the medium was changed to fresh, normal glucose
REGM/0.5% FCS. In certain plates, the D-glucose con-
centration was increased to 450 mg/dL (“high glucose”)
by the addition of a small volume of 1.0 mol/L D-glucose.
To control for a possible osmotic effect of high glucose,
0.5 mol/L D-mannitol was added to raise the mannitol
concentration to 450 mg/dL. Finally, some plates were
treated with exogenous recombinant human TGF-b1 at
1, 2, or 5 ng/mL (R&D Systems, Minneapolis, MN, USA).
The cells were harvested after 24 to 48 hours, or as specif-
ically indicated.
For proliferation studies, 5 × 104 cells were propagated
in 24-well plates (Nunclon, Roskilde, Denmark) in media
with a normal D-glucose concentration. Some wells were
treated with exogenous TGF-b1 at a concentration of 1
to 2 ng/mL or with a panselective neutralizing polyclonal
chicken anti-TGF-b antibody (R&D Systems) at a con-
centration of 5 lg/mL over a period of 8 days. Cells were
harvested in duplicate from the plates and counted with
an automated cell counter (Coulter Electronics, Hialeah,
FL, USA).
Northern analysis
At the end of the incubation period, cells were washed
in RNAse-free phosphate-buffered saline (PBS) (pH
7.2) and directly lysed and denatured in TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). Total cellular RNA
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was extracted according to the manufacturer’s instruc-
tions. Fifteen micrograms of RNA per lane were sep-
arated on a 1.0% agarose gel containing 0.67 mol/L
formaldehyde, transferred to a Gene-Screen nylon mem-
brane (NEN Research Products, Boston, MA, USA)
by capillary blotting, and cross-linked with ultraviolet
light. The integrity and equal loading of RNA sam-
ples were assessed by methylene blue staining of the
transferred RNA. The cDNA probes used in the studies
were separated from their plasmids in low-melt agarose
and labeled with 32P-deoxycytidine triphosphate (dCTP)
(Amersham, Piscataway, NJ, USA) using a random-
priming kit (Ready-to-Go) (Amersham). The cDNA
probes encoding murine TGF-b1, TGF-b types I and II
receptors, and fibronectin were used for Northern hy-
bridization as previously described [17, 32]. The cDNA
probes encoding murine TGF-b2 and TGF-b3, kindly
provided by Dr. Harold L. Moses, were a 442 bp EcoRI-
XhoI fragment from pmTGF-b2-9A11C and a 609 bp
BamHI-XhoI fragment from pmTGF-b3-11C [33, 34].
Labeled cDNAs were separated from unincorporated
nucleotides by passage over a Nensorb purification car-
tridge (NEN Research Products), and membranes were
hybridized with 106 cpm/mL of probe. Hybridization,
washing, and autoradiography were performed as pre-
viously reported [8]. Afterward, Northern membranes
were probed for the housekeeping gene, glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). Data on another
housekeeping gene, 28S rRNA, were obtained from the
positive image of the methylene blue–stained nylon mem-
brane [8, 35]. Autoradiograms were then quantitated by
computer-assisted video densitometry. Using NIH Image
1.62c, the mRNA level was calculated relative to that of
GAPDH or 28S. Measurements of this ratio in cells cul-
tured in “normal glucose” REGM were assigned a rela-
tive value of 100%.
Western immunoblotting
Wild-type or knockout cells were washed in ice-cold
1× PBS and then lysed in RIPA buffer [50 mmol/L
Tris-HCl, pH 8.0, 150 mmol/L NaCl, 1% Nonidet P-40,
0.1% sodium dodecyl sulfate (SDS), 1 mmol/L ethylene-
diaminetetraacetic acid (EDTA), 0.5 mmol/L dithiothre-
itol (DTT), 1 mmol/L phenylmethylsulfonyl fluoride, and
5 lg/mL each of aprotinin and leupeptin]. The cell lysate
was spun at 12,000 × g for 10 minutes, and the supernatant
containing total cellular protein was saved. The concen-
tration of protein was measured by the Lowry assay
(Bio-Rad, Hercules, CA, USA), and afterwards the pro-
tein was prepared in Laemmli sample buffer and boiled
for 5 minutes. Equal amounts of protein (20 to 25 lg) were
subjected to SDS 4% to 12% gradient polyacrylamide
gel electrophoresis (PAGE) using the NuPAGE system
(Invitrogen). Electrophoresed proteins were transferred
to a nitrocellulose membrane (Bio-Rad). After block-
ing with 5% nonfat milk in Tris-buffered saline-0.1%
Tween-20 (TBS-T), pH 7.6, the membrane was probed for
16 hours at 4◦C with one of the following primary an-
tibodies: rabbit anti-TGF-b1 (Promega, Madison, WI,
USA), rabbit anti-TGF-b2, rabbit anti-TGF-b3, rabbit
anti-TGF-b type I receptor, or rabbit anti-TGF-b type II
receptor (all from Santa Cruz Biotechnologies, Inc., Santa
Cruz, CA, USA). After three washes in TBS-T, mem-
branes were probed with a donkey antirabbit antibody
conjugated to horseradish peroxidase (Amersham Bio-
sciences, Buckinghamshire, England). The peroxidase-
catalyzed chemiluminescence reaction was developed
with SuperSignal West Pico substrate (Pierce Biotechnol-
ogy, Rockford, IL, USA), allowing the detection of im-
munoreactive protein bands. Finally, the membrane was
probed with mouse anti-b-actin antibody (Sigma Chemi-
cal Co., St. Louis, MO, USA) to serve as a loading control.
Flow cytometry
Single-cell suspensions were prepared by harvesting
wild-type and knockout cells from subconfluent T-75
flasks. Cells were washed in ice-cold PBS/1% bovine
serum albumin (BSA) and 5 mmol/L EDTA, pH 8.0
(staining buffer), and aliquots of 1 × 106 cells were
resuspended in 50 lL staining buffer. Indirect stain-
ing for TGF-b type II receptor was performed for 20
minutes on ice with a primary anti-type II receptor
antibody (Santa Cruz Biotechnologies, Inc.) or an
isotype-matched control antibody (rabbit IgG) (Pierce).
Washed cells were then incubated a second time on
ice with goat anti-rabbit IgG-fluorescein isothiocyanate
(FITC) (Boehringer Mannheim, Mannheim, Germany).
Stained cells were washed and resuspended in stain-
ing buffer. Propidium iodide (Sigma Chemical Co.) at
2 lg/mL was added to cell suspensions, and fluorescence
was recorded on a FACScan cytofluorograph (Becton
Dickinson; Mountain View, CA, USA). Data were an-
alyzed with CELL Quest software. In each run, at least
10,000 gated events (propidium iodide excluded) were
analyzed.
Tritiated thymidine incorporation
Wild-type and knockout cells (1 × 104 cells/well)
were subcultured in flat-bottomed, 96-well plastic plates
(Nunclon) and were rested overnight in serum-free
REGM with a D-glucose concentration of 130 mg/dL.
Fresh REGM/0.5% FCS with a normal (130 mg/dL) or a
high (450 mg/dL) D-glucose concentration or an equiv-
alent D-mannitol concentration (450 mg/dL) was then
added. Cells were grown for an additional 48-hour pe-
riod, and in the last 6 hours of growth, 1 lCi of [3H]-
thymidine (5 Ci/mmol) (Amersham) was added to each
well. Cells were lysed with trypsin at 37◦C and the nuclei
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were harvested on glass-fiber paper and counted for scin-
tillations as previously described [9, 36]. Data are shown
as percentages of the control.
Tritiated leucine incorporation
Wild-type and knockout cells (1 × 105 cells/well) were
seeded onto 24-well culture plates and at 50% to 60%
confluence were rested overnight in serum-free, normal
glucose REGM. Afterward, the medium was changed to
fresh REGM/0.5% FCS with a normal (130 mg/dL) or a
high (450 mg/dL) D-glucose concentration or an equiv-
alent D-mannitol concentration (450 mg/dL). In the last
16 hours of culture, 1 lCi of L-[4,5-3H] leucine (73.0 Ci/
mmol) (Amersham) was applied to each well. After a
total of 48 hours in normal glucose, high glucose, or man-
nitol, cells were washed and leucine incorporation was
assayed as previously described [20]. Leucine incorpora-
tion was divided by the cell number per well, determined
from a 24-well plate incubated in parallel and counted
using a Bright-Line Hemacytometer (Hausser Scientific,
Horsham, PA, USA). Data are presented as percentages
of the control.
Protein content measurement
For determination of protein content, wild-type and
knockout cells grown in 24-well plates were exposed to
REGM/0.5% FCS containing normal glucose (130 mg/
dL), high glucose (450 mg/dL), or mannitol (450 mg/dL)
for 48 hours. The cells were then lysed in equal volumes of
RIPA buffer (50 mmol/L Tris-HCl, pH 8.0, 150 mmol/L
NaCl, 1% Nonidet P-40, 0.1% SDS, 1 mmol/L EDTA,
0.5 mmol/L DTT) per well to extract the total cellular
protein. After a 10-minute spin at 4◦C and 12,000 × g to
pellet the cellular debris, the concentration of the cellu-
lar proteins in the supernatant was measured by the DC
Protein Assay (modified Lowry assay), according to the
manufacturer’s instructions (Bio-Rad). The total protein
content was then normalized for the cell number, counted
as above. Data are shown as percentages of the control.
Fibronectin enzyme-linked immunosorbent
assay (ELISA)
The cell culture supernatants from wild-type and
knockout cells exposed to 24 hours of normal glucose,
high glucose, mannitol, or TGF-b1 were assayed for fi-
bronectin protein content by a commercial ELISA kit,
according to the manufacturer’s instructions (Exocell,
Philadelphia, PA, USA). In brief, culture media were
added for 30 minutes to the wells of a microtiter plate
precoated with a gelatin to adsorb the fibronectin. Af-
ter several washes, an antifibronectin antibody directly
conjugated to horseradish peroxidase was added to each
well for an additional 30 minutes. After further washes,
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Fig. 1. Knockout cells from transforming growth factor-b1 (TGF-b1)
knockout mice lack TGF-b1 mRNA and protein. Northern analysis and
Western blotting performed on wild-type (WT) and knockout (KO)
cells demonstrate that wild-type cells express all three mammalian
isoforms of TGF-b . Although knockout cells lack TGF-b1, they do
express message and protein for TGF-b2 and TGF-b3. GAPDH is
glyceraldehyde-3-phosphate dehydrogenase.
the horseradish peroxidase-catalyzed colorimetric reac-
tion was developed with a tetramethyl benzidine (TMB)
substrate and stopped with an acid solution. The ab-
sorbance was read on a microplate reader at 450 nm.
The fibronectin concentrations of the supernatants were
determined from the standard curve, plotted as the log
of fibronectin concentration against the absorbance at
450 nm. For each experimental condition, fibronectin
concentrations were corrected for the respective total
RNA content, and the results are expressed as percent-
ages of the control.
RESULTS
Knockout cells lack TGF-b1 but express the other
components of the TGF-b system
Northern analysis performed on total cell RNA from
wild-type and knockout cells demonstrates that knock-
out cells lack transcripts for TGF-b1, as expected, but
do express transcripts for TGF-b2and TGF-b3 (Fig. 1).
TGF-b2 mRNA is resolved as two bands, which is likely
due to alternative splicing [33, 37]. The expression of
TGF-b3 appears to be greater in knockout cells (Fig. 1).
By Western immunoblotting, TGF-b1 protein is absent
in knockout cells, whereas TGF-b2 and TGF-b3 are both
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Fig. 2. Constitutive expression of the transforming growth factor-b (TGF-b) type I receptor (TbRI) that is increased by exogenous TGF-b1.
Northern analysis and Western blotting show (A) greater gene expression and protein production of the type I receptor at baseline in wild-type
(WT) compared with knockout (KO) cells, all under normal glucose conditions. (B) mRNA expression of the type I receptor in both wild-type
and knockout cells is stimulated by treatment with 2 ng/mL TGF-b1 for 24 hours. (C) Quantities of type I receptor protein are stimulated in both
wild-type and knockout cells by 2 ng/mL TGF-b1 for 48 hours. Representative autoradiograms and immunoblots are shown, and graphs depict the
mean ± SEM of the relative densities of the type I receptor bands corrected for 28S rRNA or b-actin, with control values arbitrarily set to 100%
(N = 3 to 5 independent experiments). ∗P < 0.05 vs. wild-type or normal glucose (NG) control.
present in knockout cells (Fig. 1). The amount of TGF-b3
protein is visibly increased in knockout cells compared to
wild-type, consistent with the mRNA data by Northern
analysis.
The two cell types engage in gene expression and pro-
tein production of the TGF-b type I receptor (Fig. 2)
and the type II receptor (Fig. 3), both belonging to the
family of transmembrane serine-threonine kinase recep-
tors. Type II is the primary or ligand-binding receptor,
because it forms a high-affinity complex with TGF-b and
then binds to the type I receptor. The type II receptor
phosphorylates and activates the type I receptor, which
can then transduce a signal. While wild-type cells have
a higher steady-state mRNA level of the type I receptor
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Fig. 3. Constitutive expression of the transforming growth factor-b (TGF-b) type II receptor (TbRII) that is decreased by exogenous TGF-b1. (A)
Northern analysis and Western blotting show greater gene expression and protein production of the type II receptor at baseline in knockout (KO)
compared with wild-type (WT) cells, all under normal glucose conditions. (B) mRNA expression of the type II receptor in both wild-type and
knockout cells is inhibited by treatment with 2 ng/mL TGF-b1 for 24 hours. (C) Quantities of type II receptor protein are reduced in both wild-type
and knockout cells by treatment with 2 ng/mL TGF-b1 for 48 hours. Representative autoradiograms and immunoblots are shown, and graphs depict
the mean ± SEM of the relative densities of the type II receptor bands corrected for 28S rRNA or b-actin, with control values arbitrarily set to
100% (N = 3 to 4 independent experiments). ∗P < 0.05 vs. wild-type or normal glucose (NG) control.
(wild-type 100% ± 9.5% vs. knockout 44% ± 1.7% of
wild-type control, N = 3, P < 0.005) (Fig. 2A), knock-
out cells demonstrate a significantly greater expression of
the type II receptor (wild-type 100% ± 10% vs. knock-
out 241% ± 9% of wild-type control, N = 3, P < 0.005)
(Fig. 3A). Likewise, by Western blotting, wild-type cells
contain more type I receptor protein (wild-type 100% ±
7.0% vs. knockout 55% ± 7.4% of wild-type control, N =
5, P < 0.005) (Fig. 2A), but knockout cells possess more
type II receptor protein (wild-type 100% ± 20.6% vs.
knockout 213% ± 3.3% of wild-type control, N = 4, P <
0.005) (Fig. 3A).
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Fig. 4. Cell surface expression of the transforming growth factor-b (TGF-b) type II receptor protein evaluated by the use of an anti-type II receptor
antibody in fluorescence-activated cell sorting (FACS). Treatment with 5 ng/mL of TGF-b1 for 72 hours (thin solid line) decreases the type II
receptor cell surface expression from baseline (thick solid line) in both wild-type (A) and knockout cells (B). Control Ig (dashed line), matched for
the species and isotype of the anti-type II receptor antibody, shows the degree of nonspecific binding of antibodies.
Modulation of type I and type II receptor expression
by TGF-b1
To examine the role of TGF-b1 in regulating its type I
and type II receptors, further analyses were performed on
TGF-b1–treated wild-type and knockout cells. As shown
in Figure 2B, exogenous TGF-b1 markedly stimulates
the gene expression of the type I receptor in both wild-
type and knockout cells, with knockout cells displaying
the larger relative increase. Specifically, in response to
2 ng/mL of TGF-b1 for 24 hours, type I receptor mRNA
increases by 2.4-fold in wild-type cells (239% ± 20% of
control, N = 3, P = 0.01) (Fig. 2B) and by 3.4-fold in
knockout cells (343% ± 20% of control, N = 3, P <
0.005) (Fig. 2B). At the protein level, type I receptor in-
creases by nearly 50% in wild-type cells (146% ± 18%
of control, N = 4, P < 0.05) (Fig. 2C) and by ∼30% in
knockout cells (131% ± 10% of control, N = 3, P < 0.05)
(Fig. 2C) when stimulated with 2 ng/mL of TGF-b1.
In stark contrast, exposure to exogenous TGF-b1 sig-
nificantly inhibits the mRNA expression of the type II
receptor in both wild-type and knockout cells. By den-
sitometric analysis, the steady-state mRNA level of the
type II receptor is decreased by ∼20% in wild-type cells
(TGF-b1 82% ± 7% of control, N = 4, P < 0.05) (Fig. 3B)
and by ∼40% in knockout cells (TGF-b1 62% ± 6% of
control, N = 4, P < 0.005) (Fig. 3B). TGF-b1 treatment
also decreases the quantity of type II receptor protein. In
wild-type cells, type II receptor declines by ∼30% (67% ±
6.9% of control, N = 4, P < 0.01) (Fig. 3C), and in knock-
out cells, type II receptor decreases by almost 50% (53%
± 5.4% of control, N = 4, P < 0.001) (Fig. 3C). The in-
hibitory effect of TGF-b1 on the type II receptor is clearly
seen in the representative Western blots (Fig. 3C). Ad-
ditionally, the effect of TGF-b1 on the quantity of the
ligand-binding type II receptor protein located on the
cell membrane was evaluated by fluorescence-activated
cell sorting (FACS), both at baseline (unstimulated)
and after 72 hours of treatment with 5 ng/mL TGF-b1
(Fig. 4). Compared with the respective unstimulated con-
trols, wild-type cells show a 45% decline in surface type
II receptor protein, and knockout cells manifest a 30%
decrease in type II receptor on the cell surface (Fig. 4).
Knockout cells demonstrate a rapid basal rate
of proliferation that is slowed by TGF-b1 addition
TGF-b normally inhibits the replication of proximal
tubular cells [38], so the absence of TGF-b1 may be ex-
pected to increase the proliferation rate. Serial cell count-
ing demonstrates that the two knockout cell lines have a
doubling time between 1 and 2 days vs. a doubling time of
5 days seen in the two wild-type cell lines (Fig. 5). By day
5, both of the knockout cell lines showed significantly
greater fold increases in cell number than either of the
wild-type cell lines (Fig. 5).
In a separate experiment, the effects of TGF-b block-
ade and TGF-b1 restoration were tested on the prolif-
eration rates of wild-type and knockout cells. Treatment
with a neutralizing, panselective chicken polyclonal anti-
TGF-b antibody (5 lg/mL) significantly increases the
rate of proliferation of wild-type cells (Fig. 6). Although
they proliferate more rapidly with TGF-b deactivated,
the wild-type cells still do not divide as quickly as the
knockout cells (Fig. 6). The addition of anti-TGF-b anti-
body does not increase the proliferation of knockout cells
any further. On the other hand, addition of exogenous
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Fig. 6. Antiproliferative effect of endogenous transforming growth
factor-b1 (TGF-b1) in wild-type (WT) tubular epithelial cells. Equal
numbers of WT 3.5 and KO 2.4 cells were seeded at day 0. Blockade of
endogenous TGF-b in wild-type cells with a panselective, chicken poly-
clonal, neutralizing anti-TGF-b antibody (aT) increases the wild-type
proliferation rate, although this still lags behind the knockout (KO) pro-
liferation rate. Knockout cells divide much more rapidly than wild-type
cells, and the addition of neutralizing anti-TGF-b antibody (aT) has no
discernible effect on the knockout cell count at day 8. However, supply-
ing exogenous TGF-b1 to the knockout cells retards their replication.
Graph depicts the mean ± SEM of the fold increase in cell number at
day 8 (N = 3 independent experiments). ∗P < 0.05 vs. WT 3.5 control;
†P < 0.05 vs. KO 2.4 control.
TGF-b1 (1 ng/mL) inhibits the replication of knockout
cells (Fig. 6).
In high glucose, knockout cells do not undergo
hypertrophy, contrary to the wild-type cells
The accepted definition of cellular hypertrophy is an
increase in protein synthesis or protein content without a
concurrent increase in the DNA content or cell number.
Tritiated thymidine incorporation and cell counting were
used to gauge DNA replication and proliferation, while
tritiated leucine incorporation and a modified Lowry as-
say were used to evaluate protein synthesis rate and
cellular protein content. Wild-type cells treated with high
glucose for 48 hours decrease their incorporation of
thymidine by 8% (92% ± 1.9% of control, N = 5, P <
0.05) (Fig. 7A), while wild-type cells exposed to an equiv-
alent concentration of mannitol display a similar decrease
in thymidine incorporation (87% ± 2.5% of control,
N = 5, P < 0.05) (Fig. 7A). On the other hand, knockout
cells exposed to high glucose for 48 hours react by in-
creasing their thymidine incorporation (126% ± 9.5%
of control, N = 5, P < 0.05) (Fig. 7A). Mannitol has
no effect on thymidine incorporation in knockout cells
(100% ± 4.5% of control, N = 5, P = NS) (Fig. 7A).
The thymidine data are corroborated by the cell counts.
The number of wild-type cells after 48 hours in high glu-
cose declines significantly by 11% (89% ± 3.1% of con-
trol, N = 4, P < 0.05) (Fig. 7B) and by 16% in mannitol
(84% ± 3.1% of control, N = 4, P < 0.05) (Fig. 7B). In
contrast, the number of knockout cells increases by 15%
after 48 hours of high glucose (115% ± 4.1% of control,
N = 4, P < 0.05) (Fig. 7B), and the knockout cell count
is not influenced by mannitol (99% ± 4.0% of control,
N = 4, P= NS) (Fig. 7B).
As a marker of protein synthetic rate, tritiated leucine
incorporation per cell increases by a significant amount
in wild-type cells exposed to high glucose for 48 hours,
rising by 50% over the control value (150% ± 2.4% of
control, N = 6, P < 0.05) (Fig. 8A). Mannitol exerts an
effect similar to high glucose on wild-type cells, increas-
ing the leucine incorporation per cell by 55% (155% ±
4.2% of control, N = 6, P < 0.005) (Fig. 8A). However,
knockout cells behave differently from wild-type and re-
spond to high glucose with a decrease in leucine incorpo-
ration per cell (69% ± 1.9% of control, N = 6, P < 0.005)
(Fig. 8A). Unlike high glucose, though, mannitol does
not significantly affect the leucine incorporation per
knockout cell (92% ± 3.3% of control, N = 6, P= NS)
(Fig. 8A).
Consistent with the leucine incorporation data, the pro-
tein content per cell increases by 42% in wild-type cells
exposed to high glucose (142% ± 2.2% of control, N =
3, P < 0.05) (Fig. 8B) and by 40% in wild-type treated
with mannitol (140% ± 2.4% of control, N = 3, P < 0.05)
(Fig. 8B). On the other hand, with knockout cells, high
glucose causes the protein content per cell to decrease by
15% (85% ± 1.7% of control, N = 3, P < 0.05) (Fig. 8B),
whereas mannitol does not significantly alter the amount
of total protein per cell (104% ± 1.2% of control, N =
3, P= NS) (Fig. 8B). Taken together with the thymidine
and cell number figures from above, the protein data in-
dicate that high glucose and mannitol can induce cellular
hypertrophy in wild-type cells but not in knockout cells.
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Fig. 7. Divergent effects of high glucose on
thymidine incorporation and cell count in
wild-type (WT) and transforming growth
factor-b1 (TGF-b1) knockout (KO) cells. (A)
Wild-type and knockout cells were grown in
96-well plates for 48 hours in media containing
normal glucose (NG) (130 mg/dL), high glu-
cose (HG) (450 mg/dL), or mannitol (Mann)
(450 mg/dL) and then were labeled with [3H]-
thymidine in the last 6 hours. Scintillations
(cpm) were counted and results are shown as
the mean ± SEM of the thymidine incorpo-
ration as percentages of the control, assigned
a value of 100%. In wild-type cells both high
glucose and mannitol reduced thymidine in-
corporation, a measure of DNA replication,
and in knockout cells high glucose but not
mannitol stimulated thymidine incorporation.
(B) Wild-type and knockout cells were seeded
in 12-well plates and exposed to media con-
taining normal glucose, high glucose, or man-
nitol for 48 hours. After trypsinization, the
cells were scraped and resuspended in a fixed
volume of media containing 10% fetal calf
serum (FCS). The number of cells per well
was counted in a Bright-Line Hemacytome-
ter. Data are presented as the mean ± SEM
of the cell counts as percentages of the con-
trol, assigned a value of 100%. Both high glu-
cose and mannitol decreased the number of
wild-type cells, and high glucose but not man-
nitol increased the number of knockout cells
(N = 5 independent experiments for thymi-
dine and N = 4 independent experiments for
cell count). ∗P < 0.05 vs. control.
Knockout cells exhibit decreased fibronectin at baseline
but respond exuberantly to exogenous TGF-b1
At baseline under normal glucose conditions, North-
ern analysis shows that knockout cells have a signifi-
cantly reduced steady-state mRNA level of fibronectin
compared with wild-type cells (Fig. 9A). Neverthe-
less, exogenous treatment with TGF-b1 (2 ng/mL) for
24 hours significantly increases fibronectin gene expres-
sion in both wild-type and knockout cells. In wild-type
cells, TGF-b1 causes fibronectin mRNA to increase by
more than sixfold (635% ± 94% of wild-type control,
N =6, P <0.005) (Fig. 9A), and in knockout cells, TGF-b1
raises fibronectin mRNA by more than eightfold (832%
± 106% of knockout control, N = 5, P < 0.005). The
enormous fold increase for knockout cells is a bit mis-
leading, however, because knockout cells express much
less fibronectin than wild-type cells in general. Not un-
til knockout cells are stimulated with TGF-b1 does fi-
bronectin expression become greater than in wild-type
controls (147% ± 19% of wild-type control, N = 5, P <
0.01) (Fig. 9A). In other words, the relative increase in fi-
bronectin with TGF-b1 may be greater for knockout cells
(∼eightfold vs. ∼sixfold), but the absolute amount of fi-
bronectin mRNA in knockout cells, even with TGF-b1
stimulation, just barely surpasses the fibronectin level of
wild-type cells at baseline (Fig. 9A). From the same exper-
iments as above, cell culture supernatants were assayed
for fibronectin protein by ELISA. TGF-b1 treatment for
24 hours causes wild-type cells to enrich their media by
∼1.7-fold more fibronectin (171% ± 12% of control, N =
4, P < 0.001) (Fig. 9B) and knockout cells to increase their
media level of fibronectin protein by 1.24-fold (124% ±
16% of control, N = 5, P < 0.05). Again, to provide the
proper perspective, the absolute quantity of fibronectin
protein in knockout cells still lags behind that of wild-type
cells (Fig. 9B).
High glucose-induced fibronectin expression is severely
blunted in knockout cells
Exposure to high glucose for 24 hours causes the wild-
type cell to increase its quantity of fibronectin mRNA
by ∼70% (169% ± 23% of control, N = 6, P < 0.05)
(Fig. 9A). An equal concentration of mannitol, to control
for an osmotic effect of high glucose, also stimulates fi-
bronectin expression in wild-type cells, but only by ∼35%
(134% ± 16% of control, N = 6, P = 0.05) (Fig. 9A).
At the protein level, fibronectin in the cell culture su-
pernatant increases by ∼30% during treatment with high
glucose for 24 hours (133% ± 3% of control, N = 4, P =
0.05) (Fig. 9B). Mannitol, however, does not significantly
raise the fibronectin protein content in the culture media
of wild-type cells (115% ± 10% of control, N = 4, P=
NS) (Fig. 9B).
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Fig. 8. Divergent effects of high glucose on
leucine incorporation and protein content
in wild-type (WT) and transforming growth
factor-b1 (TGF-b1) knockout (KO) tubuloep-
ithelial cells. (A) Wild-type and knockout
cells were grown for 48 hours in media con-
taining normal glucose (NG) (130 mg/dL),
high glucose (HG) (450 mg/dL), or mannitol
(Mann) (450 mg/dL) and then were labeled
with [3H]-leucine in the last 16 hours. Scintil-
lations (cpm) were adjusted for the cell num-
ber and results are shown as the mean ± SEM
of the leucine incorporation per cell as per-
centages of the control, assigned a value of
100%. In wild-type cells, both high glucose
and mannitol significantly stimulate leucine
incorporation, a measure of protein synthetic
rate, and, in knockout cells, high glucose but
not mannitol inhibits leucine incorporation.
(B) Wild-type and knockout (KO) cells were
seeded onto 24-well plates and exposed to me-
dia containing normal glucose, high glucose,
or mannitol for 48 hours. The cells were then
lysed in standardized volumes of RIPA buffer,
and the cellular protein concentrations were
measured by a modified Lowry assay. Total
protein content was calculated and corrected
for the cell number, counted in identically
treated wells of the 24-well plate. Results are
presented as the mean ± SEM of the pro-
tein content per cell as percentages of the
control, assigned a value of 100%. In wild-
type cells, both high glucose and mannitol
increased the protein content per cell, and,
in knockout cells, high glucose but not man-
nitol lowered the protein content per cell
(N = 6 independent experiments for leucine
and N = 3 independent experiments for pro-
tein content). ∗P < 0.05 vs. control.
On the other hand, the TGF-b1 knockout cell manages
only a 23% increase in fibronectin mRNA in response to
high glucose (123% ± 5% of knockout control, N = 5,
P < 0.01). Considering that knockout cells have a much
lower basal expression of fibronectin than wild-type cells
(Fig. 9A), the relatively small effect of high glucose on
knockout cell expression of fibronectin is probably incon-
sequential. This is borne out by the ELISA data showing
minimal effect of high glucose on fibronectin protein in
the cell culture media of knockout cells (104% ± 6% of
control, N = 5, P= NS) (Fig. 9B). Mannitol fails to in-
crease the level of either fibronectin mRNA (110% ±
22% of control, N = 5, P= NS) (Fig. 9A) or fibronectin
protein (101% ± 7% of control, N = 5, P= NS) (Fig. 9B)
in knockout cells.
DISCUSSION
Interventional studies using panselective anti-TGF-b
therapy have elucidated the critical role that TGF-b
plays in the pathogenesis of diabetic nephropathy. By
specifically blocking the effects of all of the TGF-b
isoforms, neutralizing anti-TGF-b antibodies have pre-
vented mesangial matrix expansion and the develop-
ment of renal isufficiency in mouse models of diabetes,
even though hyperglycemia and proteinuria were persis-
tent [17, 18]. Other strategies that have been employed
to inhibit the TGF-b system in animal models and in
cell culture include the use of antisense oligonucleotides,
decorin, and a dominant-negative TGF-b receptor [39–
41]. The ability to inhibit the TGF-b system with bi-
ologic molecules represents an important advance, but
techniques to create gene knockouts allow one compo-
nent of the TGF-b system to be obliterated entirely. Of
the three mammalian TGF-b isoforms, TGF-b1 was tar-
geted because it alone circulates in the bloodstream, is
the most highly expressed isoform in the kidney, and has
been most closely linked to the pathophysiology of dia-
betic nephropathy [21]. However, the TGF-b1 knockout
mouse dies at an early age so studying the role of TGF-b1
in diabetic kidney disease would be nearly impossible in
this animal model.
To circumvent the longevity problem, kidney cells from
the TGF-b1 knockout mouse were established as primary
cell culture lines, yielding knockout 2.3 and knockout 2.4.
These knockout cells and their wild-type counterparts ap-
pear to be derived from the proximal tubular epithelium.
As expected, cells from TGF-b1 knockout mice do not
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Fig. 9. Markedly decreased constitutive
expression of fibronectin and attenuated
stimulation of fibronectin by high glucose
in knockout (KO) compared with wild-type
(WT) cells. (A) Northern analysis of equal
amounts of total RNA from wild-type and
knockout cells demonstrates vastly greater
quantities of fibronectin mRNA in wild-type
vs. knockout cells under all conditions,
normal glucose (N or NG), high glucose
(H or HG), mannitol (M or Mann), and
transforming growth factor-b1 (TGF-b1) (T)
for 24 hours. The 28S band was generated
from the positive image of the Northern
membrane stained with methylene blue. High
glucose significantly stimulates fibronectin
expression by 69% in wild-type cells but only
by 23% in knockout cells, relative to their
own baseline levels. Mannitol, an osmotic
control for high glucose, produces a 34%
increase of fibronectin mRNA in wild-type
cells but does not alter fibronectin expression
in knockout cells. Exogenous TGF-b1
dramatically stimulates fibronectin expres-
sion in both wild-type and knockout cells. A
representative autoradiogram is shown, and
the graph depicts the mean ± SEM of the
relative densities of the fibronectin bands
corrected for 28S rRNA, all in relation to the
wild-type control, which is assigned a value of
100% (N = 5 to 6 independent experiments).
∗P < 0.05 vs. wild-type control (NG); +P =
0.05 vs. mannitol (Mann); and †P < 0.05
vs. knockout control (NG). (B) Enzyme-
linked immunosorbent assay (ELISA) for
fibronectin protein performed on the cell
culture media of wild-type and knockout
cells treated with normal glucose (NG), high
glucose (HG), mannitol (Mann), or TGF-b1
for 24 hours. Under all conditions, fibronectin
protein levels are significantly lower in
knockout cells than in wild-type cells. High
glucose increases fibronectin protein in the
media of wild-type cells by 33% but fails to
stimulate fibronectin production by knockout
cells. Mannitol has no significant effect in
either cell line. Finally, exogenous TGF-b1
increases fibronectin in both wild-type and
knockout cells. Graph displays the mean ±
SEM of the fibronectin protein corrected for
total RNA content, all as percentages of the
wild-type control, which is assigned a value of
100% (N = 4 to 5 independent experiments).
∗P ≤ 0.05 vs. wild-type control; †P < 0.05 vs.
knockout control.
express TGF-b1, but they still express message and pro-
tein for the TGF-b2 and -b3 isoforms. These three iso-
forms share similar actions in vitro but not necessarily
in vivo [42]. It is unclear if TGF-b2 and TGF-b3 can
“compensate” for the loss of the TGF-b1 isoform in the
knockout cells. However, the fact that a panselective,
neutralizing anti-TGF-b antibody had little effect on the
proliferation rate of knockout cells (Fig. 6) supports the
notion that the TGF-b1 isoform exerts the predominant
effect on cell proliferation. In addition, the markedly de-
creased levels of fibronectin mRNA and protein in knock-
out cells compared with wild-type proves that TGF-b1
is essential for maintaining even a normal degree of fi-
bronectin expression (Fig. 9). Among the three isoforms,
TGF-b1 appears to be the most potent stimulator of ex-
tracellular matrix expression.
The knockout cells also express message and protein
for the signaling type I and type II receptors and are able
to respond to exogenous TGF-b1 with decreased cellular
proliferation (Fig. 6) and increased fibronectin expression
(Fig. 9). Compared with wild-types, however, knockout
cells express significantly less type I receptor, but interest-
ingly, more of the ligand-binding type II receptor. In both
cell types, exogenous TGF-b1 down-regulates the type II
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receptor, at the mRNA and protein levels and at the cell
surface (Figs. 3B and C and 4), consistent with a known
negative feedback physiology [43–45]. Accordingly, the
increased expression of the type II receptor in knock-
out cells can be explained by the complete absence of
TGF-b1, which would remove its inhibitory effect on the
type II receptor (Fig. 3A). On the other hand, exogenous
TGF-b1 up-regulates type I receptor mRNA and protein
(Fig. 2B and C). This interesting result has been reported
in human prostate smooth muscle cells [43], keloid fibrob-
lasts [46], and ocular fibroblasts [47], but to our knowl-
edge this has not been previously shown in renal tubule
cells. Because TGF-b1 stimulates type I receptor expres-
sion, a complete lack of TGF-b1 in knockout cells prob-
ably explains their reduced type I receptor message and
protein at baseline vs. wild-type cells (Fig. 2A).
Given that knockout cells have decreased type I re-
ceptor but increased type II receptor, it is difficult to pre-
dict how the balance of TGF-b receptors will affect the
function of exogenously provided TGF-b1. There may be
discrete subsets of TGF-b–mediated responses (e.g., mi-
togenesis vs. fibrogenesis) that are differentially regu-
lated by the two receptors [43]. For instance, the type
I receptor may be more important in promoting fibrotic
responses [41, 43], while the type II receptor may be more
involved with inhibiting cellular proliferation [43, 48].
Consistent with these postulates, the knockout cells with
their decreased type I receptor do not attain the same de-
gree of TGF-b1–induced fibronectin mRNA or protein as
the wild-type cells (Fig. 9), and with their increased type
II receptor the knockout cells appear to be exquisitely
sensitive to the antiproliferative effects of TGF-b1
(Fig. 6).
Compared with the wild-type cell lines, both of the
knockout clones demonstrate significantly greater rates
of basal proliferation that may be partially due to the
absence of TGF-b1 expression in these cells. This find-
ing is consistent with the known antiproliferative effect
of TGF-b1 on tubuloepithelial cells [9, 11]. Restoring
TGF-b1 in the culture media of the knockout cells
markedly diminishes their proliferation such that the
cell number drops to the level of the wild-type cells
(Fig. 6). Conversely, shielding the wild-type cells from
the effects of ambient TGF-b (with anti-TGF-b anti-
body) increases their proliferation so that the cell count
surpasses the number of untreated wild-type cells but
still lags behind the number of TGF-b1 knockout cells
(Fig. 6). Perhaps the knockout cells outgrow the wild-
type cells treated with anti-TGF-b therapy because the
gene knockout completely deletes TGF-b1, whereas
the neutralizing antibody may only partially intercept
TGF-b1.
We had previously shown that high glucose induces hy-
pertrophy in cultured renal proximal tubule cells [9]. In
the current study, high glucose causes the wild-type cells
to increase their protein synthesis, assayed by leucine in-
corporation and measurement of total protein per cell,
and to decrease their proliferation, determined by thymi-
dine incorporation and cell counts (Figs. 7 and 8). Since
these effects on wild-type cells were replicated by man-
nitol, the mechanism of high glucose-induced cellular hy-
pertrophy is likely related to hyperosmolarity. However,
the TGF-b1 knockout cells respond to high glucose in
just the opposite manner. They show decreased rates
of protein synthesis (by leucine incorporation per cell)
and decreased protein content per cell (Fig. 8) and ex-
hibit increased thymidine incorporation and cell number
(Fig. 7), a profile inconsistent with cellular hypertro-
phy but compatible with hyperplasia. Moreover, unlike
the case with wild-type cells, the high glucose effects
on knockout cells were not reproduced by mannitol
(Figs. 7 and 8). Thus, high glucose causes cellular hyper-
trophy in wild-type cells likely by an osmotic effect, that
itself is dependent on the expression of TGF-b1 in these
cells. In the absence of TGF-b1, high glucose in knockout
cells stimulates cellular proliferation rather than hyper-
trophy, and this phenomenon is not related to hyperos-
molarity since mannitol had no demonstrable effect.
As for extracellular matrix expression, the TGF-b1-
knockout cells can increase their mRNA and protein lev-
els of fibronectin in response to exogenous TGF-b1. At
baseline, the knockout cells have significantly lower levels
of fibronectin compared with wild-type cells, suggesting
that the absence of TGF-b1 decreases the basal rate of
matrix expression (Fig. 9). After treatment with TGF-
b1, the knockout cells display a striking increase in fi-
bronectin mRNA and protein, proving that these cells
have an otherwise competent TGF-b signaling system
that can stimulate matrix production. The wild-type cells
also respond to TGF-b1 treatment with a vigorous in-
crease in fibronectin. Although the absolute amount of
TGF-b1–induced fibronectin message and protein are
greater in wild-type cells (Fig. 9), the percentage in-
crease in fibronectin mRNA from baseline is greater for
the knockout cells (Fig. 9A). Our findings are similar to
those of another paper looking at wild-type and TGF-b1
knockout cells that showed greater basal production of
collagen IV in wild-type cells but a greater relative in-
crease in TGF-b1–stimulated collagen IV expression in
knockout cells [27].
Whereas knockout cells react exuberantly to exoge-
nous TGF-b1, they respond to high glucose with a tiny
but statistically significant increase in fibronectin mRNA
(Fig. 9A). However, the biologic impact of this finding
is questionable since high glucose does not stimulate fi-
bronectin protein production significantly in knockout
cells (Fig. 9B). In contrast, the wild-type cells respond
to high glucose with a significant increment in both fi-
bronectin message and protein (Fig. 9). This reinforces
the concept that high glucose induces matrix expression
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by a TGF-b–dependent mechanism and perhaps more
specifically by a TGF-b1–dependent mechanism. The ef-
fect of high glucose to stimulate fibronectin does not ap-
pear to be mediated much by either TGF-b2 or TGF-b3,
because knockout cells possess both of these isoforms
but do not show any change in fibronectin protein when
treated with high glucose (Fig. 9B). This supports our pre-
vious findings in cultured kidney cells that high glucose
increases matrix by stimulating the production of TGF-
b1 that then acts in autocrine fashion to induce matrix
[6, 9, 11, 20, 49]. A minor component of the profibrotic
effect of high glucose in wild-type cells may be related
to hyperosmolarity, since exposure to an equivalent con-
centration of mannitol produced a small but significant
increase in fibronectin mRNA (Fig. 9A). Mannitol treat-
ment also produced a tiny rise in fibronectin protein, but
this did not reach statistical significance (Fig. 9B). A gen-
uine effect of mannitol cannot be ruled out, however, as
others have reported mannitol increasing fibronectin
message and protein in mesangial cells, perhaps at-
tributable to transcriptional activation at the activated
protein-1 (AP-1) site of the fibronectin promoter [50].
Regardless of the exact contribution of an osmotic nature,
high glucose requires the participation of the TGF-b sys-
tem, and in particular TGF-b1, to mediate its fibrogenic
impact in diabetic nephropathy.
CONCLUSION
Cultured tubuloepithelial cells from the TGF-b1
knockout mouse provide an interesting in vitro tool to
study the specific role of TGF-b1 in renal diseases such
as diabetic nephropathy. The knockout cells appear to
have an otherwise intact TGF-b system in that they ex-
press TGF-b2, TGF-b3, and the TGF-b type I and type
II receptors. However, the mere absence of TGF-b1 in
knockout cells confers an increased proliferative capac-
ity, a resistance to the hypertrophic effects of high glucose,
and a muted sclerotic response to high glucose. Therefore,
TGF-b1 appears to be the most prominent isoform in
the pathogenesis of tubular hypertrophy and tubuloint-
erstitial fibrosis, which are characteristic of and maladap-
tive in diabetic nephropathy.
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